Print

Purpose

This study is being done to learn about the safety and effects of the study drugs, PF-08653945 and PF-08653944, when given alone or together for weight loss, compared to a placebo (a dummy drug that has no active ingredient in it).

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

Eligible participants for this study include: - adults aged 18 years or older with - obesity (BMI of 30.0 kg/m2 to 50.0 kg/m2) or with - overweight (BMI of 27.0 kg/m2 to <30.0 kg/m2) who also have at least 1 prespecified weight-related comorbidity (hypertension, dyslipidemia, cardiovascular disease, or obstructive sleep apnea), at the screening visit.

Exclusion Criteria

Participants who are not eligible include those with diabetes mellitus, a body weight change of >5% or use of weight loss medications in the 12 weeks prior to screening, a history of or plan for surgical treatment for obesity, and those who are unable or unwilling to comply with contraceptive requirements or are pregnant or lactating.

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Double (Participant, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Cohort 1 		Participants receive subcutaneous injections of PF-08653945 or placebo.
  • Drug: PF-08653945
    Subcutaneous Injection
  • Drug: Placebo
    Subcutaneous Injection
Experimental
Cohort 2 		Participants receive subcutaneous injections of PF-08653945 + PF-08653944 or placebo.
  • Drug: PF-08653945
    Subcutaneous Injection
  • Drug: PF-08653944
    Subcutaneous Injection
  • Drug: Placebo
    Subcutaneous Injection
Experimental
Cohort 3 		Participants receive subcutaneous injections of PF-08653945 + PF-08653944 , PF-08653944 , or placebo.
  • Drug: PF-08653945
    Subcutaneous Injection
  • Drug: PF-08653944
    Subcutaneous Injection
  • Drug: Placebo
    Subcutaneous Injection

Recruiting Locations

Diablo Clinical Research, LLC dba Flourish Research
Walnut Creek, California 94598

Mercury Street Medical Group, PLLC
Butte, Montana 59701

AB Clinical Trials
Las Vegas, Nevada 89119

DelRicht Research
Charlotte, North Carolina 28210

Monroe Biomedical Research
Monroe, North Carolina 28112

Piedmont Healthcare
Statesville, North Carolina 28625

DelRicht Research
Hendersonville, Tennessee 37075

JCCT-JUNO NW Houston
Houston, Texas 77040

DM Clinical Research
Tomball, Texas 77375

More Details

Status
Recruiting
Sponsor
Pfizer

Study Contact

Pfizer CT.gov Call Center
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.